Advanced search
Publication Cover
Leukemia & Lymphoma Volume 52, 2011 - Issue sup2
Submit an article Journal homepage
567
Views
16
CrossRef citations to date
0
Altmetric
Articles

Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia

Robert J. KreitmanLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USACorrespondence[email protected]
,
Evgeny AronsLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
,
Maryalice Stetler-StevensonLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
,
David J. P. FitzgeraldLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
,
Wyndham H. WilsonMetabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
&
Ira PastanLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Pages 82-86 | Published online: 23 May 2011

References

  • Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003;21:891–896.
  • Grever MR. Pentostatin: impact on outcome in hairy cell leukemia. Hematol Oncol Clin North Am 2006;20:1099–1108.
  • Sigal DS, Sharpe R, Burian C, Saven A. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood 2010;115:1893–1896.
  • Else M, Dearden CE, Matutes E, Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009;145:733–740.
  • Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med 2007;58:221–237.
  • Kreitman RJ, Wilson WH, Robbins D, Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 1999;94:3340–3348.
  • Kreitman RJ, Wilson WH, White JD, Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000;18: 1614–1636.
  • Kreitman RJ, Wilson WH, Bergeron K, Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001;345: 241–247.
  • Kreitman RJ, Squires DR, Stetler-Stevenson M, Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005;23: 6719–6729.
  • Salvatore G, Beers R, Margulies I, Kreitman RJ, Pastan I. Improved cytotoxic activity towards cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res 2002;8:995–1002.
  • Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003;102:810–813.
  • Ravandi F, Jorgensen JL, O'Brien SM, Eradication of minimal residual disease in hairy cell leukemia. Blood 2006;107:4658–4662.
  • Robinson KS, Williams ME, van der Jagt RH, Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4473–4479.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.